+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
SPARC

Sun Pharma Advanced Research Company Share Price

₹218.35 +11.08 (5.35%)
102.18% Gain from 52W Low

05 Aug, 2026 3:58 PM (IST)

Sun Pharma Advanced Research Company live price: ₹218.35. It opened at ₹210 vs previous close ₹207; intraday high/low: ₹221/₹207. The 50 & 200 DMA stand at ₹217.60/₹178.00.

Sun Pharma Advanced Research Company Performance

  • Today's Low
  • ₹207
  • Today's High
  • ₹221
  • 52 Week Low
  • ₹108
  • 52 Week High
  • ₹289
  • Open Price₹210
  • Previous Close₹207
  • Volume2,351,460
  • 50 DMA₹217.60
  • 100 DMA₹197.80
  • 200 DMA₹178.00

Sun Pharma Advanced Research Company Chart

Investment Returns

  • Over 1 Month -8.78%
  • Over 3 Month + 56.3%
  • Over 6 Month + 54.52%
  • Over 1 Year + 46.93%

Smart Investing Starts Here Start SIP with Sun Pharma Advanced Research Company for Steady Growth!

Invest Now

Sun Pharma Advanced Research Company Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 4.6
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 7,086
  • P/B Ratio
  • 5.3
  • Average True Range
  • 10.5
  • EPS
  • 47.9
  • Dividend Yield
  • 0
  • MACD Signal
  • -6.6
  • RSI
  • 46.53
  • MFI
  • 25.52

Latest Stock News Updates

Sun Pharma Advanced Research Company Ltd - 532872 - Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results For The Quarter Ended June 30, 2026

Sun Pharma Advanced Research Company Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026

Sun Pharma Advanced Research Company Ltd - 532872 - Intimation For Receipt Of Requests For Reclassification Of Shareholder Category

Intimation for Receipt of Request for Reclassification of Shareholder Category

Sun Pharma Advanced Research Company Ltd - 532872 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Advertisement of 21st Annual General Meeting of Company and related information

Sun Pharma Advanced Research Company Financials

Sun Pharma Advanced Research Company Technicals

EMA & SMA

Current Price
₹218.35
+ 11.08 (5.35%)
pointer
  • Bearish Moving Average 5
  • Bullish Moving Average 11
  • 20 Day
  • ₹221.50
  • 50 Day
  • ₹217.60
  • 100 Day
  • ₹197.80
  • 200 Day
  • ₹178.00

Resistance and Support

215.25 Pivot Speed
  • R3 238.40
  • R2 229.60
  • R1 224.00
  • S1 209.60
  • S2 200.90
  • S3 195.20

Sun Pharma Advanced Research Company Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-10 Quarterly Results
2026-05-18 Audited Results
2026-02-09 Quarterly Results
2026-01-14 To consider issue of Warrants & ESOP
2025-11-10 Quarterly Results

Sun Pharma Advanced Research Company Shareholding Pattern

65.67%
30.34%
3.9%
0.08%
0.01%

About Sun Pharma Advanced Research Company

Sun Pharma Advanced Research Company is engaged in the business of research and development (R&D) of pharmaceutical products. View More
  • NSE Symbol
  • SPARC
  • BSE Symbol
  • 532872
  • ISIN
  • INE232I01014

Similar Stocks to Sun Pharma Advanced Research Company

Sun Pharma Advanced Research Company FAQs

Sun Pharma Advanced Research Company share price is ₹218 As on 05 August, 2026 | 21:14

The Market Cap of Sun Pharma Advanced Research Company is ₹7085.9 Cr As on 05 August, 2026 | 21:14

The P/E ratio of Sun Pharma Advanced Research Company is 4.6 As on 05 August, 2026 | 21:14

The PB ratio of Sun Pharma Advanced Research Company is 5.3 As on 05 August, 2026 | 21:14

The 52 week High & Low of Sun Pharma Advanced Research Company is ₹289/₹108 respectively As on 05 August, 2026 | 21:14

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23